We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
76
Protara Therapeutics
TARA
$226M
$4.9M 0.29%
940,512
-196,287
-17% -$1.16M
ABVX
77
CALL
Abivax
ABVX
$9.89B
$4.9M 0.29%
+44,000
New +$5.21M
AGIO icon
78
Agios Pharmaceuticals
AGIO
$1.99B
$4.76M 0.28%
140,672
-47,328
-25% -$1.34M
LLY icon
79
Eli Lilly
LLY
$1.05T
$4.65M 0.27%
+5,060
New +$5.13M
DNTH icon
80
Dianthus Therapeutics
DNTH
$5.92B
$4.62M 0.27%
+55,000
New +$3.19M
ARWR icon
81
Arrowhead Research
ARWR
$12B
$4.41M 0.26%
70,300
+12,100
+21% +$766K
BLTE
82
Belite Bio
BLTE
$6.11B
$4.29M 0.25%
26,880
-12,959
-33% -$2.18M
EVMN
83
Evommune Inc
EVMN
$480M
$4.23M 0.25%
184,062
– –
MLYS icon
84
Mineralys Therapeutics
MLYS
$2.26B
$4.19M 0.25%
154,686
+18,455
+14% +$541K
JANX icon
85
Janux Therapeutics
JANX
$1.1B
$4.15M 0.24%
298,546
+53,094
+22% +$728K
CLYM
86
Climb Bio
CLYM
$837M
$4.09M 0.24%
597,662
-834,813
-58% -$4.82M
PALI icon
87
Palisade Bio
PALI
$349M
$3.96M 0.23%
2,264,845
+260,000
+13% +$473K
AEXA
88
American Exceptionalism Acquisition Corp
AEXA
$569M
$3.87M 0.23%
357,539
– –
SPRB
89
Spruce Biosciences
SPRB
$175M
$3.83M 0.23%
58,600
+600
+1% +$41.4K
NAMS icon
90
NewAmsterdam Pharma
NAMS
$3.1B
$3.8M 0.22%
118,623
– –
LQDA icon
91
PUT
Liquidia Corp
LQDA
$6.06B
$3.77M 0.22%
100,000
+75,500
+308% +$2.8M
ZURA icon
92
Zura Bio
ZURA
$548M
$3.75M 0.22%
630,403
+68,338
+12% +$413K
ACLX
93
DELISTED
Arcellx
ACLX
$3.68M 0.22%
32,084
+600
+2% +$53K
CTNM
94
Contineum Therapeutics
CTNM
$641M
$3.61M 0.21%
276,661
-2,300
-0.8% -$30.9K
GLUE icon
95
Monte Rosa Therapeutics
GLUE
$1.14B
$3.55M 0.21%
215,752
– –
ONC
96
BeOne Medicines Ltd
ONC
$41.5B
$3.47M 0.2%
+11,701
New +$3.79M
TENX icon
97
Tenax Therapeutics
TENX
$79.7M
$3.41M 0.2%
213,462
+149,789
+235% +$2.03M
AVBP icon
98
ArriVent BioPharma
AVBP
$1.49B
$3.27M 0.19%
+141,814
New +$3.2M
PLRX icon
99
Pliant Therapeutics
PLRX
$68.7M
$3.26M 0.19%
2,585,126
+2,511,307
+3,402% +$3.17M
ATAI icon
100
AtaiBeckley Inc
ATAI
$2.7B
$3.23M 0.19%
913,242
– –
2 3
4
5 6

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.